Total Payments
$2.2M
2024 Payments
$203,137
Companies
60
Transactions
4,474
Medicare Patients
37,053
Medicare Billing
$28.2M
Payment Breakdown by Category
Other$1.6M (70.1%)
Travel$302,146 (13.6%)
Consulting$241,699 (10.9%)
Food & Beverage$104,331 (4.7%)
Research$13,048 (0.6%)
Education$909.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 838 | 67.5% |
| Travel and Lodging | $302,146 | 509 | 13.6% |
| Consulting Fee | $241,699 | 125 | 10.9% |
| Food and Beverage | $104,331 | 2,920 | 4.7% |
| Honoraria | $58,074 | 49 | 2.6% |
| Unspecified | $13,048 | 4 | 0.6% |
| Education | $909.96 | 29 | 0.0% |
Payments by Type
General
$2.2M
4,470 transactions
Research
$13,048
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $585,804 | 1,072 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $386,111 | 294 | $0 (2024) |
| ABBVIE INC. | $282,377 | 567 | $0 (2024) |
| Lilly USA, LLC | $172,105 | 290 | $0 (2024) |
| UCB, Inc. | $131,238 | 301 | $0 (2024) |
| Janssen Biotech, Inc. | $123,173 | 328 | $0 (2024) |
| PFIZER INC. | $121,773 | 300 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $73,852 | 182 | $0 (2024) |
| GlaxoSmithKline, LLC. | $46,121 | 128 | $0 (2024) |
| Horizon Therapeutics plc | $42,054 | 81 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $203,137 | 430 | ABBVIE INC. ($45,990) |
| 2023 | $248,367 | 497 | Amgen Inc. ($65,607) |
| 2022 | $200,470 | 507 | Amgen Inc. ($76,884) |
| 2021 | $207,066 | 461 | Amgen Inc. ($65,124) |
| 2020 | $193,034 | 406 | Amgen Inc. ($56,046) |
| 2019 | $433,530 | 752 | Amgen Inc. ($107,923) |
| 2018 | $376,681 | 740 | Janssen Scientific Affairs, LLC ($113,178) |
| 2017 | $352,931 | 681 | Amgen Inc. ($101,149) |
All Payment Transactions
4,474 individual payment records from CMS Open Payments — Page 1 of 179
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $275.00 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Organon Llc | HADLIMA (Drug), RENFLEXIS | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 12/20/2024 | Organon Llc | HADLIMA (Drug), RENFLEXIS | Food and Beverage | In-kind items and services | $0.83 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 12/19/2024 | Genentech USA, Inc. | Actemra (Biological), Rituxan | Food and Beverage | In-kind items and services | $169.51 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $6.38 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $106.33 | General |
| Category: Bone Health | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Immunology | ||||||
| 12/15/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $625.50 | General |
| Category: Bone Health | ||||||
| 12/13/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 12/12/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $22.26 | General |
| 12/07/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $113.10 | General |
| 12/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $92.65 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Rheumatology | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $124.99 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Comparative and Pragmatic Study of Simponi Aria Versus | Janssen Research & Development, LLC | $10,102 | 2 |
| Ph 3 PMO Treatment (20030216) Extension | Amgen Inc. | $2,076 | 1 |
| Safety and Efficacy of Denosumab Among Subjects in the FREEDOM Extension Study With Mild-to-Moderat | Amgen Inc. | $869.87 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 8,659 | 522,121 | $32.4M | $6.4M |
| 2022 | 44 | 9,579 | 574,211 | $33.1M | $6.8M |
| 2021 | 49 | 8,954 | 584,833 | $30.6M | $7.2M |
| 2020 | 49 | 9,861 | 548,565 | $29.8M | $7.8M |
Total Patients
37,053
Total Services
2,229,730
Medicare Billing
$28.2M
Procedure Codes
186
All Medicare Procedures & Services
186 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 378 | 209,758 | $15.3M | $2.2M | 14.3% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 99 | 33,627 | $4.9M | $1.1M | 23.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 514 | 40,685 | $2.2M | $745,654 | 33.9% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 44 | 107,408 | $2.6M | $417,056 | 16.2% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 24 | 72,060 | $1.1M | $336,856 | 31.2% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 11 | 2,800 | $1.0M | $308,864 | 29.7% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 66 | 34,230 | $889,980 | $270,692 | 30.4% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 22 | 3,770 | $938,385 | $226,379 | 24.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 546 | 1,846 | $599,908 | $169,932 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 987 | 1,395 | $362,531 | $123,368 | 34.0% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 926 | 2,583 | $697,370 | $102,037 | 14.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 612 | 1,575 | $275,475 | $80,465 | 29.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 20 | 2,821 | $727,560 | $73,737 | 10.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 329 | 421 | $147,350 | $53,104 | 36.0% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 464 | 930 | $69,750 | $23,655 | 33.9% |
| 73100 | X-ray of wrist, 2 views | Office | 2023 | 459 | 921 | $64,470 | $21,836 | 33.9% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 441 | 885 | $61,950 | $21,263 | 34.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 506 | 506 | $101,200 | $17,239 | 17.0% |
| 72050 | X-ray of upper spine, 4-5 views | Office | 2023 | 420 | 421 | $46,310 | $15,153 | 32.7% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 106 | 152 | $47,823 | $12,881 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 84 | 84 | $42,840 | $12,809 | 29.9% |
| 72072 | X-ray of middle spine, 3 views | Office | 2023 | 244 | 244 | $20,008 | $6,683 | 33.4% |
| 73564 | X-ray of knee, 4 or more views | Office | 2023 | 88 | 176 | $16,016 | $5,651 | 35.3% |
| 73522 | X-ray of both hips, 3-4 views | Office | 2023 | 131 | 131 | $14,803 | $4,893 | 33.1% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 90 | 180 | $12,600 | $4,421 | 35.1% |
About Dr. Aaron Broadwell, MD
Dr. Aaron Broadwell, MD is a Rheumatology healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1851554786.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaron Broadwell, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $203,137 received in 2024. These payments were reported across 4,474 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Broadwell has provided services to 37,053 Medicare beneficiaries, totaling 2,229,730 services with total Medicare billing of $28.2M. Data is available for 4 years (2020–2023), covering 186 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Shreveport, LA
- Active Since 07/10/2008
- Last Updated 08/21/2012
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1851554786
Products in Payments
- STELARA (Biological) $294,977
- Enbrel (Biological) $161,286
- Prolia (Biological) $151,914
- SIMPONI ARIA (Biological) $149,735
- Cimzia (Drug) $123,676
- EVENITY (Biological) $123,558
- RINVOQ (Biological) $117,420
- XELJANZ (Drug) $114,445
- TALTZ (Drug) $113,910
- Otezla (Drug) $85,462
- ACTHAR (Biological) $73,037
- TREMFYA (Drug) $59,116
- KRYSTEXXA (Biological) $46,138
- BENLYSTA (Biological) $45,984
- COSENTYX (Biological) $40,714
- KEVZARA (Biological) $30,301
- Rinvoq (Biological) $25,764
- RINVOQ (Drug) $23,561
- Tymlos (Biological) $21,849
- TAVNEOS (Drug) $21,521
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Shreveport
Frankie Pedigo, Md, MD
Rheumatology — Payments: $45,338
Rheumatology $45,338
Larry Broadwell, Md, MD
Rheumatology — Payments: $43,198
Rheumatology $43,198
Robert Goodman, M.d, M.D
Rheumatology — Payments: $19,291
Rheumatology $19,291
Mary Walton, M.d, M.D
Rheumatology — Payments: $17,623
Rheumatology $17,623
Thomas Pressly, Md, MD
Rheumatology — Payments: $12,800
Rheumatology $12,800
Samina Hayat, Mbbs, MBBS
Rheumatology — Payments: $7,878
Rheumatology $7,878